Anavex Life Sciences Corp. — Form 10-Q Summary
Reporting period: Fiscal first quarter ended December 31, 2023. The interim financial statements are unaudited. Anavex is a clinical-stage biopharmaceutical company developing treatments for CNS diseases; it has generated no operating revenue.
Key financial metrics
| Metric | Quarter ended Dec. 31, 2023 | Comparable 2022 quarter / prior balance-sheet date |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $8.7 million | $12.1 million |
| General and administrative expense | $2.6 million | $3.3 million |
| Total operating expenses / operating loss | $11.3 million | $15.4 million |
| Other income, net | $2.8 million | $2.4 million |
| Net loss / loss per share | $8.6 million / $0.11 | $13.0 million / $0.17 |
| Operating cash flow | $(7.3) million | $(5.8) million |
| Cash and cash equivalents | $143.8 million | $151.0 million at Sept. 30, 2023 |
| Working capital | $135.6 million | $141.9 million at Sept. 30, 2023 |
| Total liabilities | $12.5 million | $12.5 million at Sept. 30, 2023 |
Margins are not meaningful because the company has no operating revenue. No borrowings or interest-bearing debt are reported on the balance sheet. Cash declined $7.3 million during the quarter; option exercises provided $59,000 in financing cash flow.
Changes versus the prior comparable period
- Operating expenses fell $4.1 million, primarily due to lower stock-based compensation and lower external trial costs as the Rett EXCELLENCE trial and Alzheimer’s Phase 2b/3 trial had completed.
- Net loss narrowed by $4.4 million, reflecting reduced operating expenses and higher interest income. Interest income rose to $2.0 million from $1.3 million, attributed to higher returns on cash investments.
- Despite the lower net loss, operating cash use increased by $1.5 million, principally because prior-period working-capital movements were more favorable.
- Weighted-average shares increased to 82.1 million from 78.0 million. Quarter-end shares were 82.1 million; 14.3 million options and warrants were excluded from diluted loss per share as anti-dilutive.
Outlook, clinical developments and risks
- Management believes existing working capital will fund requirements for more than 12 months after issuance of the statements. It expects negative operating cash flows to continue and cannot predict when, if ever, the company will become profitable.
- Management expects R&D spending to rise as it advances Alzheimer’s and Rett syndrome extension studies, pursues Parkinson’s disease development, and plans trials of ANAVEX 3-71 in schizophrenia and ANAVEX 2-73 in Fragile X syndrome.
- The filing reports January 2024 topline results for the pediatric Rett EXCELLENCE study: the RSBQ co-primary endpoint showed improvement, but the other co-primary endpoint, CGI-I, was not met. An ad hoc 12-week RSBQ comparison did not reach statistical significance (p=0.063); a week-four comparison was statistically significant (p=0.041). The company reported no new preliminary safety signals.
- Funding options include a Lincoln Park purchase agreement with $122.1 million remaining available as of Dec. 31, 2023, subject to contractual conditions and potential dilution. No shares were sold under it during the quarter. The company said it was currently unable to sell shares under its at-the-market Sales Agreement.
- Australian R&D tax incentive claims are subject to review; claims for 2019–2022 remain open to potential review, and the company has not recorded an allowance for possible adjustments, repayments, penalties or interest.
- The company reports ordinary-course litigation but does not expect pending matters to have a material adverse effect. It reported no material changes to previously disclosed risk factors, no material changes in market-risk exposure, and effective disclosure controls as of Dec. 31, 2023.
Important facts for investors to verify
- Full statistical results and regulatory implications of the Rett EXCELLENCE trial, including the missed CGI-I endpoint and the status of further Rett development.
- Clinical and regulatory plans, timelines, and costs for Alzheimer’s, Parkinson’s, Rett, schizophrenia and Fragile X programs.
- Cash-burn trends and whether the stated liquidity outlook remains adequate as planned trial spending increases.
- Availability and terms of future financing, including practical access to the Lincoln Park facility and the status of the currently unavailable ATM facility.
- Potential dilution from outstanding options, warrants and future equity sales, including the 150,000 warrants expiring May 6, 2024.
- Eligibility and possible review outcomes for Australian R&D tax incentives.